(Q38152532)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

The Wnt/β-catenin pathway in ovarian cancer: a review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Rebecca C Arend

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Angelina I Londoño-Joshi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

J Michael Straughn

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

11 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

772-779

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24125749%20AND%20SRC:MED&resulttype=core&format=json

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

The cell of origin of ovarian epithelial tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

WNT signaling in ovarian follicle biology and tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Wnt signaling in ovarian tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Roles and regulation of Wnt signaling and beta-catenin in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Wnt signaling in stem and cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Female development in mammals is regulated by Wnt-4 signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Wnt proteins induce dishevelled phosphorylation via an LRP5/6- independent mechanism, irrespective of their ability to stabilize beta-catenin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Targeting embryonic signaling pathways in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Multiplicity of the interactions of Wnt proteins and their receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Oncogenic PI3K deregulates transcription and translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

The biology of ovarian cancer: new opportunities for translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Integrin regulation of beta-catenin signaling in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

E-Cadherin Suppresses Cellular Transformation by Inhibiting β-Catenin Signaling in an Adhesion-Independent Manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

A systems biology approach reveals common metastatic pathways in osteosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Growth inhibition of ovarian tumor-initiating cells by niclosamide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Targeting Wnt signaling: can we safely eradicate cancer stem cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034

beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.09.034